Amorphous compound
AssigneeAstraZeneca AB
InventorRonald John Roberts
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel form of (S)-1-[N2-(1-carboxy-3-phenylpropyl]-L-lysyl]-L-proline known under the generic name lisinopril. Further, the present invention also relates to the use of the novel amorphous form of lisinopril for the treatment of hypertension and other cardiovascular diseases, pharmaceutical compositions containing it as well as processes for the preparation of the novel amorphous form of lisinopril.
Claims14
Amorphous lisinopril.
A compound comprising lisinopril in amorphous form, wherein the compound provides an X-ray powder diffraction pattern containing one or more broad diffuse halos and when dry, a Tg measured by TMA, of at least 100° C.
A compound which is (S)-1-[N2-(1-carboxy-3-phenylpropyl]-L-lysyl]-L-proline in amorphous form, wherein the compound provides an X-ray powder diffraction pattern containing one or more broad diffuse halos and when dry, a Tg measured by TMA, of at least 100° C.
Dependencies are inferred from the claim text.